Advertisement
U.S. markets closed
Advertisement

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
1.3200+0.0600 (+4.76%)
At close: 04:00PM EST
1.3300 +0.01 (+0.76%)
After hours: 07:27PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Performance Outlook
Previous Close1.2600
Open1.2500
Bid1.2700 x 1000
Ask1.3400 x 1000
Day's Range1.2500 - 1.3350
52 Week Range0.9900 - 2.0400
Volume217,914
Avg. Volume175,158
Market Cap69.959M
Beta (5Y Monthly)0.87
PE Ratio (TTM)3.38
EPS (TTM)0.3900
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
7% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SPRO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Spero Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • Insider Monkey

    Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript

    Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript November 13, 2023 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $-0.15. Ted Jenkins: Thank you, operator, and thank you all for participating in today’s conference call. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the third […]

  • GlobeNewswire

    Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

    Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR

  • GlobeNewswire

    Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

    CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide